What is the appropriate management for a patient with hyperthyroidism who presents with palpitations?

Management of Palpitations in Hyperthyroid Patients

Start a beta-blocker immediately to control heart rate and provide symptomatic relief from palpitations, while simultaneously initiating antithyroid medication to restore euthyroid state. 1, 2

Immediate Beta-Blocker Therapy

Beta-blockers are mandatory first-line therapy for controlling palpitations and tachycardia in hyperthyroidism. 1, 2 They provide dual benefit by:

• Controlling ventricular rate and reducing palpitations through direct cardiac effects 2
• Blocking peripheral conversion of T4 to T3, reducing circulating active thyroid hormone 1, 2
• Rapidly improving cardiac symptoms within hours to days of initiation 1

Specific Beta-Blocker Dosing

For hemodynamically stable patients with palpitations:

• Propranolol 60-80 mg orally every 4-6 hours, titrating to achieve heart rate <100 bpm 2
• Alternative options include atenolol or metoprolol in standard doses for symptomatic relief 1
• Goal is to lower heart rate to nearly normal, which improves tachycardia-mediated symptoms 1

For severe symptoms or hemodynamic instability:

• Esmolol 500 mcg/kg IV loading dose over 1 minute, followed by maintenance infusion starting at 50 mcg/kg/min 2
• Propranolol IV can be used as alternative for acute management 1

Concurrent Antithyroid Treatment

Simultaneously start antithyroid drugs (methimazole or propylthiouracil) to restore euthyroid state, as this is the cornerstone of definitive management 2, 3, 4

• Over 56% of patients experience spontaneous resolution of arrhythmias once thyroid function normalizes 2
• Cardiovascular symptoms typically resolve within weeks to months of achieving euthyroid state 1

Critical Assessment for Arrhythmias

Obtain ECG to evaluate for atrial fibrillation or atrial flutter, as these are common complications causing palpitations in hyperthyroidism 1, 2

• Patients >60 years with TSH <0.1 mIU/L have 3-5 fold increased risk of atrial fibrillation 1, 3
• If atrial fibrillation is present, initiate anticoagulation based on CHA₂DS₂-VASc score, not thyroid status alone 2
• Do not attempt cardioversion until euthyroid state is achieved (typically 4 months after normalization), as relapse risk is extremely high during active thyrotoxicosis 2

Age-Specific Considerations

Patients >50 years require particularly aggressive management, as cardiovascular complications are the chief cause of death in this population if hyperthyroidism is left untreated 1, 2, 5

• Elderly patients may require dose reduction of beta-blockers as they transition to euthyroid state 6
• **Consider treatment even for subclinical hyperthyroidism (TSH <0.1 mIU/L)** in patients >60 years due to cardiovascular mortality risk 1, 6

Common Pitfalls to Avoid

Do not delay beta-blocker initiation while waiting for antithyroid medication to take effect, as beta-blockers provide immediate symptomatic relief while antithyroid drugs take weeks to normalize thyroid function 1, 2

Do not use calcium channel blockers (diltiazem, verapamil) as first-line unless beta-blockers are contraindicated, as beta-blockers have additional benefits of blocking T4 to T3 conversion 1

Monitor for transition to hypothyroidism during treatment, as this is the most common outcome and requires adjustment of antithyroid medication 1

Assess for underlying structural heart disease in older patients, as pre-existing ischemic, hypertensive, or valvular disease can be unmasked or worsened by hyperthyroidism 1

Expected Clinical Course

Palpitations and tachycardia improve within days of beta-blocker initiation, while complete resolution typically occurs after achieving euthyroid state in 4-8 weeks 1, 2

If palpitations persist despite adequate rate control and euthyroid state, consider alternative cardiac causes or refer to cardiology for further evaluation 1